Geographic Variations in Racial Disparities for Peripheral Artery Disease Treatment in the U.S.
Key Takeaways: Black patients with peripheral artery disease (PAD) had significantly higher major amputation rates than White patients across all U.S. states (3.0% vs. 0.9%, p<0.001), with disparities varying widely…
Mitral Annular Calcification Severity Predicts Outcomes in Severe Aortic Stenosis Patients Undergoing TAVR
Key Points: The presence of mitral annular calcification (MAC) in prior studies of transcatheter aortic valve replacement (TAVR) has been associated with poor outcomes, but these studies used semiqualitative assessment,…
Impact of Technology-Enabled Home-Based Cardiac Rehabilitation on Functional Status and Cardiovascular Health Metrics: mTECH-Rehab Trial
Key Points: Cardiac rehabilitation (CR) is a guideline-directed multifaceted intervention that is shown to improve cardiovascular morbidity and mortality, but enrollment is low, especially among underrepresented groups, owing due to…
Zerlasiran Was Well Tolerated and Reduced Time-averaged Lp(a) Concentration: The ALPACAR Trial
Key Takeaways: Zerlasiran, a short interfering RNA (siRNA) targeting lipoprotein(a) (Lp(a)), was well tolerated and led to significant reductions in Lp(a) serum concentrations in both healthy participants and patients with…
AMULET IDE Trial 5 years Showed Long-term Safety and Efficacy of AMPLATZER Amulet and Watchman Device in LAAO
Key Takeaways: The AMULET IDE trial compared the AMPLATZER Amulet occluder with the Watchman 2.5 device in patients with nonvalvular atrial fibrillation (NVAF) at high risk of thromboembolism. Patients with…
ATTR-Specific Medication and AVR Improve Survival in Patients with Aortic Stenosis and ATTR Cardiac Amyloidosis
Key Takeaways: In this international registry, 266 patients with dual pathology, aortic stenosis and cardiac amyloidosis were identified and matched. A control cohort of lone AS receiving aortic valve replacement…
Bempedoic Acid Reduces Major Adverse Limb Events in Patients with PAD : A Pre-specified Analysis from the CLEAR Outcomes Trial
Key Points: Patients with peripheral artery disease (PAD) at an increased risk of both major adverse cardiovascular events (MACEs) and major adverse limb events (MALEs) Bempedoic acid is thought to…
Consistent Efficacy and Safety of Finerenone in Women and Men: A Secondary Analysis of the FINEARTS-HF Trial
KEY POINTS: Historically women have been underrepresented in cardiovascular clinical trials, however, rates of Heart Failure with Preserved Ejection Fraction are rising more rapidly in women FINEARTS-HF trial enrolled 46%…
Oral Muvalaplin Lowered Lipoprotein(a): The KRAKEN Trial
Key Takeaways: KRAKEN was an international, multicenter, placebo controlled, phase 2 trial that tested the effects of muvalaplin at different doses—10 mg, 60 mg or 240 mg, taken daily—vs placebo…
Rivaroxaban for 18 Months Superior to 6 Months To Prevent Recurrent VTE Events in Cancer Patients with Acute-low PE: ONCO PR
Key Takeaways: The ONCO PE trial demonstrated that an 18-month treatment with rivaroxaban significantly reduced recurrent venous thromboembolism (VTE) compared to a 6-month treatment in patients with cancer and acute…
Promising Cardioprotective Effect of ARNi in High-Risk Cancer Patients Treated with Anthracycline Chemotherapy: SARAH
Key Points: Anthracycline (ANT)-based chemotherapy is a known cancer treatment regimen but results in cardiotoxicity secondary to heart failure The SARAH trial explored whether the angiotensin receptor-neprilysin inhibitor (ARNi), sacubitril/valsartan,…
Semaglutide Improves CV Outcomes in Patients with Prior Coronary Artery Bypass Surgery: Insights from the SELECT Trial
Key Takeaways: In this secondary analysis of the SELECT Trial, semaglutide 2.4 mg once weekly significantly reduced the risk of major adverse cardiovascular events (MACE) in patients with or without…
VALOR-HCM: Mavacamten Reduces Long-Term Need for Septal Reduction Therapy in Symptomatic Obstructive HCM
Key Points: In patients with treatment-refractory symptomatic obstructive hypertrophic cardiomyopathy (HCM), invasive septal reduction therapies (SRT)—alcohol septal ablation or surgical myectomy—are often the last resort for symptom management. Septal reduction…
FLOW Trial: Renal Benefits of Semaglutide in T2DM Similar Regardless of Baseline CV Risk
Key Points Both chronic kidney disease (CKD) and cardiovascular disease (CVD) are prevalent in type 2 diabetes (T2DM), contributing to morbidity and mortality. The FLOW trial demonstrated that semaglutide, a…
Reconditioned Pacemakers Non-Inferior To New Pacemakers in Low- and Middle-Income Countries: Preliminary Results from My Heart Your Heart Trial
Key Points: Many patients in low- and middle-Income countries are unable to obtain new pacemaker devices. It is unknown if reconditioned pacemakers are as effective as new pacemakers. In this…
Linear Ablation Combined with EIVOM Provides Additional Benefit in Rhythm Outcomes for Persistent AF Ablation: PROMPT-AF Trial
Key Points: It is unknown if linear ablation with ethanol infusion of the vein of Marshall (EIVOM) in addition to pulmonary vein isolation (PVI) improves outcomes as compared to PVI…
Metformin and Aggressive Lifestyle Modifications Reduce AF Fibrillation Symptoms but Not Burden: Results From the TRIM-AF Trial
Key Points: Despite prior data suggesting decrease in metabolic stress may reduce atrial fibrillation (AF) progression, the effects of aggressive lifestyle and risk factor modifications (LRFM) or metformin on AF…
SUMMIT Subanalysis: Tirzepatide Reduces Symptom Burden in Patients with Obesity-Related HFpEF
Key Points Patients with heart failure with preserved ejection fraction (HFpEF) and obesity often have significant functional limitations. The SUMMIT trial demonstrated that tirzepatide (TZP), a dual GIP/GLP-1 receptor agonist,…
In a Hierarchical Composite Outcome, Finerenone Shows Reduction in HF Exacerbations in HFmrEF or HFpEF: FINEARTS
KEY POINTS: Hierarchical analysis prioritizing significant events more effectively traditional composite outcomes, offering clearer clinical guidance In a pre-specified analysis, using a win-ratio and win-odds approach, finerenone demonstrated a reduction…
Finerenone Raises Potassium but Retains Clinical Benefits with Protocol-directed Surveillance and Dose Adjustment: FINEARTS
KEY POINTS: Finerenone, a non-steroidal mineralocorticoid (MRA), increased serum potassium levels more often than placebo. However, adverse events from hyperkalemia were rare The incidence of cardiovascular death or heart failure…